Recent Updates
Recently added Catalysts
IMCC Positive Sentiment Score: 70/100

IM Cannabis to Report Fourth Quarter and Full Year 2024 Financial Results on Monday, March 31 2025 at 9:00am ET

Key Takeaway: IM Cannabis Corp. is set to report its fourth quarter and full year 2024 financial results on March 31, 2025, prior to market opening. The announcement includes a web conference for investors at 9:00 a.m. ET, providing an opportunity for a Q&A session. IMC operates in key markets such as Israel and Germany, focusing on sustainable growth and compliance within the regulated cannabis industry. The company's commitment to transparency and investor engagement is evident in its forthcoming report and conference call.

Market Sentiment Analysis

POSITIVE FACTORS

  • IM Cannabis is a leading player in the medical cannabis market.
  • The upcoming financial report indicates transparency and communication with investors.
  • The company is engaging with investors through a Q&A session post-results.

Full Press Release Details

TORONTO and GLIL YAM, Israel, March 20, 2025 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company," "IMCannabis," or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the fourth quarter and full year 2024 ended December 31, 2024, on Monday, March 31, 2025 before the market opens.
The Company will host a zoom web conference on the same day at 9:00a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration.
If you are unable to join us live, a recording of the call will be available on our website at https://investors.imcannabis.com within 24 hours after the call.
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company's focus is to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Anna Taranko, Director Investor & Public Relations
SOURCE IM Cannabis Corp.

21 %

more press release views with

Frequently Asked Questions

When will IM Cannabis report Q4 2024 results?

IM Cannabis will report its Q4 2024 results on March 31, 2025.

How can investors join the IM Cannabis results call?

Investors can register for the call via the provided Zoom link.

Where can I find the recording of the call?

The call recording will be available on IM Cannabis's website within 24 hours.

What markets does IM Cannabis operate in?

IM Cannabis operates in Israel and Germany's medical cannabis markets.

What is IM Cannabis's focus for growth?

IM Cannabis aims for sustainable growth in its highest value markets.

Last updated: Mar 20, 2025